Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.

@article{Maroto2016ExpertOO,
  title={Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.},
  author={Pablo Maroto and Eduardo Solsona and Enrique Gallardo and Bego{\~n}a Mellado and J M S{\'a}nchez Morote and Jos{\'e} {\'A}ngel Arranz and Francisco G{\'o}mez-Veiga and Miguel Unda and Miguel {\'A}ngel Climent and Antonio Alcaraz},
  journal={Critical reviews in oncology/hematology},
  year={2016},
  volume={100},
  pages={127-36}
}
Treatment of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized in recent years. It is well known that androgen receptor is still active in most patients with disease progression and serum testosterone levels <50 ng/dL. Moreover, further hormonal maneuvers, either through decreasing androgen levels (abiraterone) or by targeting the androgen receptor (AR) pathway (enzalutamide), prolong survival. In addition, a new cytostatic able to overcome docetaxel resistance… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 79 references

AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC)

ES Antonarakis, C Lu, Y Chen
J Clin Oncol • 2015
View 4 Excerpts
Highly Influenced

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate resistant prostate cancer

A Gómez de Liaño, O Reig, B Mellado
British Journal of Cancer advance online publication • 2014
View 4 Excerpts
Highly Influenced

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2014
View 13 Excerpts
Highly Influenced

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

The New England journal of medicine • 2004
View 4 Excerpts
Highly Influenced

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 6 Excerpts
Highly Influenced

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

The New England journal of medicine • 2010
View 4 Excerpts
Highly Influenced

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…